A Comparison of Smoflipid® and Intralipid® in the Early Management of Infants with Intestinal Failure

Casson, Cameron; Nguyen, Van Thu; Nayak, P. L.; Channabasappa, Nandini; Berris, Kaitlin; Panczuk, Julia; Bhiladvala, C.; Dasgupta, Tisha; Piper, Hannah G.

doi:10.1016/j.jpedsurg.2019.09.073

Cited by 23 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SMOFlipid is a lipid emulsion formulation which has been used as a source of parenteral nutrition for pediatric patients with critical illness, following major gastrointestinal tract surgery or preterm babies who were unable to tolerate enteral feeding (14,15). Small number of studies has shown that it was safe and well-tolerated among the pediatric population (16)(17)(18).…”

Section: Discussionmentioning

confidence: 99%

Case Report: The Use of Intravenous SMOFlipid Infusion to Treat Severe Asparaginase-Induced Hypertriglyceridemia in Two Pediatric Acute Lymphoblastic Leukemia Patients

2021

View full text Add to dashboard Cite

Asparaginase-induced hypertriglyceridemia can have a spectrum of clinical presentations, from being asymptomatic to having life-threatening thrombosis or hyperviscosity syndrome. At present, there is no recommendation on routine lipid monitoring during asparaginase-containing treatment phase, nor a standardized guideline on its management. Two cases are presented here to illustrate the effects of concurrent infection on asparaginase-induced hypertriglyceridemia in patients with high-risk ALL and the use of SMOFlipid infusion as a treatment option in an acute situation.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: The Use of Intravenous SMOFlipid Infusion to Treat Severe Asparaginase-Induced Hypertriglyceridemia in Two Pediatric Acute Lymphoblastic Leukemia Patients

2021

View full text Add to dashboard Cite

show abstract

“…In 2020, Casson et al reported a retrospective study that compared the infant patients from two intestinal rehabilitation centers in Dallas, Texas and Edmonton, Alberta [67]. The different strategies at initiation of PN at age 7-8 days compared the incidence and degree of cholestasis between infants with intestinal failure receiving either SMOF or Intralipid.…”

Section: Lam Et Al In 2018 Report On a Cohort Study Conducted Betweementioning

confidence: 99%

“…The different strategies at initiation of PN at age 7-8 days compared the incidence and degree of cholestasis between infants with intestinal failure receiving either SMOF or Intralipid. The hypothesis was that infants who are initiated and maintained on SMOF will have a reduced incidence and severity of cholestasis compared to those initially receiving Intralipid [67]. The authors reported that SMOFlipid use in infants did not significantly decrease the incidence or degree of cholestasis.…”

Section: Lam Et Al In 2018 Report On a Cohort Study Conducted Betweementioning

confidence: 99%

See 1 more Smart Citation

Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure

Rochling

2021

Nutrients

View full text Add to dashboard Cite

The development of intestinal failure-associated liver disease (IFALD) in pediatric and adult patients on parenteral nutrition is usually multifactorial in nature due to nutritional and non-nutritional causes. The role of lipid therapy as a contributing cause is well-established with the pathophysiological pathways now better understood. The review focuses on risk factors for IFALD development, biological effects of lipids, lipid emulsions and the mechanisms of lipid toxicity observed in laboratory animals followed by a synopsis of clinical studies in pediatric and adult patients. The introduction of fish oil-based lipid emulsions that provide partial or complete lipid replacement therapy has resulted in resolution of IFALD that had been associated with soybean oil-based therapy. Based on case reports and cohort studies in pediatric and adult patients who were at risk or developed overt liver disease, we now have more evidence that an early switch to partial or complete fish oil–based lipid therapy should be implemented in order to successfully halt and reverse IFALD.

show abstract

“…There is a bulk of information related to n-3 PUFA supplementation and PN on liver disease [ 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 ], with a significant number of clinical trials developed or in testing state ( Table 1 and Supplementary Tables S1–S9 ), showing that n-3 PUFA supplementation is a noteworthy field in medicine.…”

Section: Beneficial Effects Of N-3 Pufa In Liver Diseasesmentioning

confidence: 99%

N-3 Polyunsaturated Fatty Acids and Their Lipid Mediators as A Potential Immune–Nutritional Intervention: A Molecular and Clinical View in Hepatic Disease and Other Non-Communicable Illnesses

et al. 2021

View full text Add to dashboard Cite

In recent years, the beneficial effect of n-3 polyunsaturated fatty acids (n-3 PUFAs) intake on human health has been widely accepted in the field of immunonutrition. Today, we find a diversity of supplements based on n-3 PUFAs and/or minerals, vitamins and other substances. The main objective of this review is to discuss the importance of n-3 PUFAs and their derivatives on immunity and inflammatory status related to liver disease and other non-communicable illnesses. Based on the burden of liver diseases in 2019, more than two million people die from liver pathologies per year worldwide, because it is the organ most exposed to agents such as viruses, toxins and medications. Consequently, research conducted on n-3 PUFAs for liver disease has been gaining prominence with encouraging results, given that these fatty acids have anti-inflammatory and cytoprotective effects. In addition, it has been described that n-3 PUFAs are converted into a novel species of lipid intermediaries, specialized pro-resolving mediators (SPMs). At specific levels, SPMs improve the termination of inflammation as well as the repairing and regeneration of tissues, but they are deregulated in liver disease. Since evidence is still insufficient to carry out pharmacological trials to benefit the resolution of acute inflammation in non-communicable diseases, there remains a call for continuing preclinical and clinical research to better understand SPM actions and outcomes.

show abstract

A Comparison of Smoflipid® and Intralipid® in the Early Management of Infants with Intestinal Failure

Cited by 23 publications

References 27 publications

Case Report: The Use of Intravenous SMOFlipid Infusion to Treat Severe Asparaginase-Induced Hypertriglyceridemia in Two Pediatric Acute Lymphoblastic Leukemia Patients

Case Report: The Use of Intravenous SMOFlipid Infusion to Treat Severe Asparaginase-Induced Hypertriglyceridemia in Two Pediatric Acute Lymphoblastic Leukemia Patients

Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure

N-3 Polyunsaturated Fatty Acids and Their Lipid Mediators as A Potential Immune–Nutritional Intervention: A Molecular and Clinical View in Hepatic Disease and Other Non-Communicable Illnesses

Contact Info

Product

Resources

About